Song Zifan, Li Biaoxian, Zhang Yingxuan, Li Ruizhen, Ruan Huan, Wu Jing, Liu Qiong
Department of Medical Microbiology, School of Medicine, Nanchang University, Nanchang, China.
The First Clinical Medical College, Nanchang University, Nanchang, China.
Front Microbiol. 2020 Jun 23;11:1340. doi: 10.3389/fmicb.2020.01340. eCollection 2020.
(), a gram-negative bacterium in the human stomach with global prevalence, is relevant to chronic gastrointestinal diseases. Due to its increasing drug resistance and the low protective efficacy of some anti- vaccines, it is necessary to find a suitable adjuvant to improve antigen efficiency. In our previous study, we determined that outer membrane vesicles (OMVs), a multicomponent secretion generated by gram-negative bacteria, of were safe and could induce long-term and robust immune responses against in mice. In this study, we employed two common vaccines, outer membrane proteins (OMPs) and whole cell vaccine (WCV) to assess the adjuvanticity of OMVs in mice. A standard adjuvant, cholera toxin (CT), was used as a control. Purified OMVs used as adjuvants generated lasting anti- resistance for 12 weeks. Additionally, both systematic and gastric mucosal immunity, as well as humoral immunity, of mice immunized with vaccine and OMVs combinations were significantly enhanced. Moreover, OMVs efficiently promoted Th1 immune response, but the response was skewed toward Th2 and Th17 immunity when compared with that induced by the CT adjuvant. Most importantly, OMVs as adjuvants enhanced the eradication of . Thus, OMVs have potential applications as adjuvants in the development of a new generation of vaccines to treat infection.
幽门螺杆菌是一种在全球流行的人类胃部革兰氏阴性菌，与慢性胃肠疾病相关。由于其耐药性不断增加以及某些抗幽门螺杆菌疫苗的保护效果不佳，有必要寻找合适的佐剂来提高抗原效力。在我们之前的研究中，我们确定幽门螺杆菌的外膜囊泡（OMVs），一种革兰氏阴性菌产生的多组分分泌物，是安全的，并且能够在小鼠体内诱导针对幽门螺杆菌的长期且强烈的免疫反应。在本研究中，我们采用两种常见疫苗，外膜蛋白（OMPs）和全细胞疫苗（WCV）来评估OMVs在小鼠中的佐剂活性。一种标准佐剂霍乱毒素（CT）用作对照。用作佐剂的纯化幽门螺杆菌OMVs产生了持续12周的抗幽门螺杆菌抵抗力。此外，用疫苗和OMVs组合免疫的小鼠的全身和胃黏膜免疫以及体液免疫均显著增强。而且，OMVs有效促进Th1免疫反应，但与CT佐剂诱导的反应相比，该反应偏向Th2和Th17免疫。最重要的是，作为佐剂的OMVs增强了幽门螺杆菌的根除。因此，OMVs在新一代治疗幽门螺杆菌感染疫苗的开发中作为佐剂具有潜在应用价值。
